{"id":"NCT03460652","sponsor":"Zevra Therapeutics","briefTitle":"KP415 Open-Label Safety Study in Children (6-12 Years of Age) With ADHD","officialTitle":"A Multicenter, Dose-Optimized, Open-Label Safety Study With KP415 in Children With Attention-Deficit/Hyperactivity Disorder","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-03-13","primaryCompletion":"2019-06-20","completion":"2019-07-09","firstPosted":"2018-03-09","resultsPosted":"2021-07-19","lastUpdate":"2021-07-19"},"enrollment":282,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["ADHD"],"interventions":[{"type":"DRUG","name":"KP415 oral capsule","otherNames":["Azstarys","SDX/d-MPH"]}],"arms":[{"label":"Open-Label KP415","type":"EXPERIMENTAL"}],"summary":"This study is a multicenter, dose-optimized, open-label safety study with KP415 in children with Attention-Deficit/Hyperactivity Disorder (ADHD).","primaryOutcome":{"measure":"Subjects With Treatment-Emergent Adverse Events (TEAEs)","timeFrame":"Up to 12 months","effectByArm":[{"arm":"Treatment-Phase Safety Population","deltaMin":143,"sd":null}],"pValues":[]},"eligibility":{"minAge":"6 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":19,"countries":["United States"]},"refs":{"pmids":["37204277","36809150"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":238},"commonTop":["infections and infestations","psychiatric disorders","metabolism and nutrition disorders","investigations","nervous system"]}}